Compare Repligen Corporation Common Stock (RGEN) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Royal Bank of Canada — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Royal Bank of Canada trades at $193.47 (market cap $268.76B). The key difference: Royal Bank of Canada is far larger — about 24.1× Repligen Corporation Common Stock's market cap, and Royal Bank of Canada pays a 2.62% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Royal Bank of Canada for 48 Days on average.
| RGEN | RY | |
|---|---|---|
Market Cap | $11.14B | $268.76B |
Volume | 1,259,263 | 726,877 |
Sector | Health | Financials |
52-Week High | $194.57 | $217.87 |
52-Week Low | $102.87 | $145.31 |
Typical Hold Time | 0 Days | 48 Days |
Enterprise Value | $11.02B | $737.27B |
Dividend Yield | — | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Royal Bank of Canada (RY) trades at $194.67, up 0.99% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.07 exceeding expectations. Revenue grew to $66.53B in 2025, and net income margin improved to 32.01%. Recent news highlights record Q3 2026 results and strategic initiatives like the unified Global Transaction Banking business.
Outlook remains positive with projected 2026 revenue of $71.1B and net income of $22.7B, though stretched valuations and technical bearishness pose risks. Analyst consensus is mixed with 43% buy ratings, but institutional buying activity supports confidence. Key risks include macroeconomic sensitivity and competitive pressures in the banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
